106 related articles for article (PubMed ID: 20069504)
1. Evaluation of the predictive value of topoisomerase II alpha in patients with breast carcinoma.
Hajduk M; Olszewski WP; Smietana A
Pol J Pathol; 2009; 60(3):115-23. PubMed ID: 20069504
[TBL] [Abstract][Full Text] [Related]
2. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II alpha--a fundamental prognostic factor in breast carcinoma.
Hajduk M
Pol J Pathol; 2009; 60(2):67-75. PubMed ID: 19886180
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
Glynn RW; Miller N; Whelan MC; Kerin MJ
Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
6. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
7. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
9. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
[TBL] [Abstract][Full Text] [Related]
10. HER-2 and topoisomerase II as predictors of response to chemotherapy.
Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
[TBL] [Abstract][Full Text] [Related]
11. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
12. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
14. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kono S; Morimoto K; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S
Breast Cancer; 2010 Apr; 17(2):103-9. PubMed ID: 19657712
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
[TBL] [Abstract][Full Text] [Related]
18. Predicting anthracycline benefit: have we made any progress?
Moretti E; Oakman C; Di Leo A
Curr Opin Oncol; 2009 Nov; 21(6):507-15. PubMed ID: 19713842
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Gómez HL; Pinto JA; Olivera M; Vidaurre T; Doimi FD; Vigil CE; Velarde RG; Abugattas JE; Alarcón E; Vallejos CS
Breast; 2011 Feb; 20(1):39-45. PubMed ID: 20705464
[TBL] [Abstract][Full Text] [Related]
20. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
Gennari A; Pronzato P
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
